Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Closes $300M Acquisition of Cord Stem-Cell Company ViaCell

NEW YORK (GenomeWeb News) — PerkinElmer said today it has closed the acquisition of ViaCell, an umbilical cord blood preservation business, for around $300 million, or $7.25 a share.
 
ViaCell collects and stores stem cells from newborns’ umbilical cords that might be of medical use by the child or a relative. PerkinElmer expects the company’s flagship ViaCord technology to complement its current prenatal screening tools for the risk of chromosomal abnormalities.
 
PerkinElmer, which first announced its plan to buy the company last month, reiterated its intent to continue selling and supporting ViaCord while divesting the ViaCell therapeutic business.
  
Sales of ViaCord in 2007 are expected to be around $60 million, PerkinElmer said.

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.